The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

Sarclisa combination improves PFS in newly diagnosed transplant-ineligible MM in phase III trial

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Data from the IMROZ phase III trial demonstrated Sarclisa (isatuximab) in combination with standard-of-care bortezomib, lenalidomide and dexamethasone followed by Sarclisa-Rd (the IMROZ regimen) significantly reduced the risk of disease progression or death by 40%, compared to VRd followed by Rd in patients with newly diagnosed multiple myeloma not eligible for transplant. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

PodcastThe Directors

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”

Thomas J. Lynch Jr. and Howard A. “Skip” Burris III lead two institutions that couldn’t be more different—an NCI-designated Comprehensive Cancer Center on one side of the country and a for-profit research enterprise on the other—but they stay up at nights worrying about the same thing.
By Katie Goldberg
Sponsored

Advancing quality of life in oncology: A journey of compassion and innovation

The recent ASCO guideline update on palliative care for cancer patients represents a significant milestone in our field’s evolution. This evidence-based guidance emphasizes what I’ve advocated throughout my career—that palliative care must be integrated early and concurrently throughout the cancer journey. This holistic approach to cancer care has been my life’s work and passion. 
By Betty Ferrell
In Brief

Fenghuang “Frank” Zhan invested in inaugural Bart Barlogie Chair for Myeloma Research

Zhan, seated, with Steven Webber (left), dean of the College of Medicine and executive vice chancellor at UAMS, and UAMS chancellor Cam Patterson (right).The University of Arkansas for Medical Sciences College of Medicine invested Fenghuang “Frank” Zhan, a tenured professor of medicine and the research director of the UAMS Winthrop P. Rockefeller Cancer Institute’s Myeloma Center, in the Bart Barlogie Chair for Myeloma Research during a March 13 ceremony. 
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account